Cell therapy developer Cartesian Therapeutics (NASDAQ:RNAC) announced Tuesday that its lead asset, Descartes-08, reached the main goal in a mid-stage trial against the muscle disorder myasthenia ...

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential ...

Tuesday, Cartesian Therapeutics Inc (NASDAQ:RNAC) announced topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). Descartes-08, Cartesian’s lead ...

FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

(Reuters) -Cartesian Therapeutics said on Tuesday that its experimental therapy helped reduce symptoms of a rare, immune-related disorder, meeting the main goal in a mid-stage study. The therapy known ...

Cartesian Therapeutics, Inc. ( (RNAC)) has released its Q3 earnings. Here is a breakdown of the information Cartesian Therapeutics, Inc. presented to its investors. Cartesian Therapeutics, Inc. is a ...

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards ...

Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.